Physician profile
Bruce L Auerbach
NPI 1235139932
$27,048.44
in general payments reported to CMS, 2019-2025
20 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $980 · 2021: $213 · 2022: $2,365 · 2023: $329 · 2024: $210 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,133.34 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $7,965.82 | 2019-2022 | |
| Pfizer INC. | $2,652.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.46 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $220.23 | 2021-2025 | Verquvo, Segluromet, Steglujan |
| Novo Nordisk INC | $144.78 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $122.07 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.65 | 2022-2023 | |
| Lilly USA, LLC | $94.12 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $61.71 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $47.65 | 2019-2022 | |
| Abbott Laboratories | $42.33 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $42.00 | 2023 | |
| Acadia Pharmaceuticals INC | $31.52 | 2025 | Daybue |
| Boston Scientific Corporation | $31.08 | 2019-2023 | Watchman Access System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $29.17 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $22.12 | 2024 | Austedo Xr |
| Amarin Pharma, INC. | $15.13 | 2023 | |
| Abbvie INC. | $14.58 | 2024 | |
| Esperion Therapeutics, INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Auerbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.